Total Payments
$15,916
2024 Payments
$126.41
Companies
14
Transactions
76
Medicare Patients
4,037
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$13,500 (84.8%)
Food & Beverage$1,568 (9.9%)
Travel$847.24 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,500 | 10 | 84.8% |
| Food and Beverage | $1,568 | 63 | 9.9% |
| Travel and Lodging | $847.24 | 3 | 5.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $14,911 | 38 | $0 (2020) |
| Merck Sharp & Dohme LLC | $256.23 | 13 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $230.46 | 2 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $117.60 | 1 | $0 (2017) |
| ViiV Healthcare Company | $116.61 | 7 | $0 (2021) |
| Melinta Therapeutics, Inc. | $82.58 | 5 | $0 (2019) |
| Theratechnologies Inc. | $58.97 | 2 | $0 (2017) |
| Philips Electronics North America Corporation | $50.86 | 2 | $0 (2019) |
| Leadiant Biosciences, Inc. | $22.31 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $15.85 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $126.41 | 5 | Merck Sharp & Dohme LLC ($126.41) |
| 2021 | $52.41 | 3 | Merck Sharp & Dohme Corporation ($37.63) |
| 2020 | $23.77 | 1 | Allergan, Inc. ($23.77) |
| 2019 | $290.67 | 11 | Janssen Pharmaceuticals, Inc ($105.84) |
| 2018 | $15,079 | 43 | Allergan Inc. ($14,773) |
| 2017 | $343.24 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($117.60) |
All Payment Transactions
76 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $28.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/28/2024 | Merck Sharp & Dohme LLC | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $31.47 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/27/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/17/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/26/2021 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $24.22 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/14/2021 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: HIV | ||||||
| 04/20/2021 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/27/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/15/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/05/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/30/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/29/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $12.08 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/23/2019 | Leadiant Biosciences, Inc. | Abelcet (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: Antifungal | ||||||
| 05/01/2019 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DIFICID | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/18/2019 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $105.84 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/28/2019 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: ANTIBIOTICS | ||||||
| 02/23/2019 | Philips Electronics North America Corporation | inCourage (Device) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/06/2019 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), PIFELTRO, DIFICID | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/16/2019 | ViiV Healthcare Company | JULUCA (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: HIV | ||||||
| 12/12/2018 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/28/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/27/2018 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/31/2018 | Melinta Therapeutics, Inc. | Vabomere (Drug), Orbactiv, MINOCIN | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/26/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 1,231 | 3,356 | $953,774 | $395,511 |
| 2022 | 5 | 864 | 2,473 | $687,686 | $293,027 |
| 2021 | 5 | 822 | 2,119 | $592,414 | $253,487 |
| 2020 | 5 | 1,120 | 2,629 | $708,378 | $297,976 |
Total Patients
4,037
Total Services
10,577
Medicare Billing
$1.2M
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 503 | 1,996 | $423,152 | $196,729 | 46.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 130 | 603 | $273,762 | $106,748 | 39.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 467 | 523 | $217,568 | $75,322 | 34.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 101 | 193 | $28,564 | $12,743 | 44.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 19 | 25 | $5,800 | $2,045 | 35.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 16 | $4,928 | $1,925 | 39.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 349 | 1,393 | $295,316 | $127,366 | 43.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 85 | 447 | $202,938 | $87,062 | 42.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 327 | 351 | $146,016 | $60,921 | 41.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 90 | 262 | $38,776 | $16,083 | 41.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 20 | $4,640 | $1,594 | 34.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 292 | 1,137 | $241,120 | $102,402 | 42.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 92 | 390 | $177,060 | $77,282 | 43.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 296 | 318 | $132,084 | $56,301 | 42.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 127 | 254 | $37,592 | $15,781 | 42.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 20 | $4,558 | $1,720 | 37.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 355 | 1,207 | $255,820 | $108,479 | 42.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 399 | 448 | $186,368 | $79,030 | 42.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 92 | 394 | $178,876 | $74,107 | 41.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 263 | 569 | $84,212 | $35,058 | 41.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $3,102 | $1,301 | 42.0% |
About Dr. John Mourani, MD
Dr. John Mourani, MD is a Infectious Disease healthcare provider based in Pomona, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962460154.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Mourani, MD has received a total of $15,916 in payments from pharmaceutical and medical device companies, with $126.41 received in 2024. These payments were reported across 76 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($13,500).
As a Medicare-enrolled provider, Mourani has provided services to 4,037 Medicare beneficiaries, totaling 10,577 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Pomona, CA
- Active Since 05/04/2006
- Last Updated 08/30/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1962460154
Products in Payments
- AVYCAZ (Drug) $14,862
- INVOKANA (Drug) $230.46
- ZERBAXA (Drug) $133.27
- JARDIANCE (Drug) $117.60
- RECARBRIO (Drug) $64.11
- TRIUMEQ (Drug) $59.24
- EGRIFTA (Drug) $58.97
- Baxdela (Drug) $53.48
- JULUCA (Drug) $42.59
- ISENTRESS (Drug) $34.63
- DALVANCE (Drug) $30.02
- Respiratoriy Care Undiv (Device) $29.28
- Vabomere (Drug) $29.10
- DIFICID (Drug) $24.22
- Abelcet (Drug) $22.31
- inCourage (Device) $21.58
- TEFLARO (Drug) $18.21
- Cresemba (Drug) $15.85
- PREZCOBIX (Drug) $14.86
- DOVATO (Drug) $14.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Pomona
Dr. Paras Udani, Do, DO
Infectious Disease — Payments: $85,602
Infectious Disease $85,602
Dr. Manish Trivedi, M.d, M.D
Infectious Disease — Payments: $72,933
Infectious Disease $72,933
Dr. Kerry Gott, M.d, M.D
Infectious Disease — Payments: $3,092
Infectious Disease $3,092
Vinod Dhawan, Md, MD
Infectious Disease — Payments: $268.59
Infectious Disease $268.59
Daniel Gluckstein, M.d, M.D
Infectious Disease — Payments: $264.56
Infectious Disease $264.56
Ms. Irene Bakman, Md, MD
Infectious Disease — Payments: $211.09
Infectious Disease $211.09